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Abstract—The use of antagonists of the mineralocorticoid receptor in the treatment of myocardial hypertrophy and heart
failure has gained increasing importance in the last years. The cardiac Na1/H1 exchanger (NHE-1) upregulation induced
by aldosterone could account for the genesis of these pathologies. We tested whether aldosterone-induced NHE-1
stimulation involves the transactivation of the epidermal growth factor receptor (EGFR). Rat ventricular myocytes were
used to measure intracellular pH with epifluorescence. Aldosterone enhanced the NHE-1 activity. This effect was
canceled by spironolactone or eplerenone (mineralocorticoid receptor antagonists), but not by mifepristone (glucocor-
ticoid receptor antagonist) or cycloheximide (protein synthesis inhibitor), indicating that the mechanism is mediated by
the mineralocorticoid receptor triggering nongenomic pathways. Aldosterone-induced NHE-1 stimulation was abolished
by the EGFR kinase inhibitor AG1478, suggesting that is mediated by transactivation of EGFR. The increase in the
phosphorylation level of the kinase p90RSK and NHE-1 serine703 induced by aldosterone was also blocked by AG1478.
Exogenous epidermal growth factor mimicked the effects of aldosterone on NHE-1 activity. Epidermal growth factor
was also able to increase reactive oxygen species production, and the epidermal growth factor–induced activation of the
NHE-1 was abrogated by the reactive oxygen species scavenger N-2-mercaptopropionyl glycine, indicating that reactive
oxygen species are participating as signaling molecules in this mechanism. Aldosterone enhances the NHE-1 activity
via transactivation of the EGFR, formation of reactive oxygen species, and phosphorylation of the exchanger. These
results call attention to the consideration of the EGFR as a new potential therapeutic target of the cardiovascular
pathologies involving the participation of aldosterone. (Hypertension. 2011;58:912-919.) ● Online Data Supplement
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The investigation of the role of aldosterone in cardiovas-cular pathophysiology has gained increasing interest in
the last few years because of relevant results obtained from
clinical studies, particularly the Randomized Aldactone Eval-
uation Study, Eplerenone Postacute Myocardial Infarction
Heart Failure Efficacy and Survival Study, and Eplerenone in
Mild Patients Hospitalization and Survival Study in Heart
Failure, in which antagonists of the mineralocorticoid recep-
tor (MR) importantly reduced mortality in patients with left
ventricular dysfunction.1–4 Aldosterone has been shown to
induce left ventricular hypertrophy independently from its
classic effects on regulation of renal Na1 and blood pres-
sure.5–7 However, the cellular, subcellular, and molecular
bases for this effect are not yet understood. Fujisawa et al8
demonstrated that the mineralocorticoid/salt-induced rat car-
diac fibrosis and hypertrophy were prevented by the selective
Na1/H1 exchanger (NHE-1) blocker cariporide. It has also
been reported that aldosterone upregulates the expression and
function of the NHE-19–12 and that selective blockade of this
transporter prevents and/or reverts left ventricular hypertro-
phy in various animal models.13 Therefore, we focused our
attention on the intracellular pathway that involves aldoste-
rone and NHE-1 as trigger and end point target, respectively.
Steroids, including aldosterone, are able to interact with
peptide hormone signaling. The epidermal growth factor
(EGF) and its receptor (EGFR) represent one of these signals
involving aldosterone.14,15 It has been shown that spironolac-
tone reduces the EGFR mRNA synthesis after cerebral
ischemia.16 Accordingly, Grossmann et al15 reported that MR
activation by aldosterone enhanced EGFR expression via an
interaction with the EGFR promoter of vascular smooth
muscle. In addition to the genomic effects, nongenotropic
actions of aldosterone concerning EGFR transactivation have
also been reported.17,18
The EGFR belongs to the ErbB family of tyrosine kinase
membrane receptors that is composed of 4 members, EGFR/
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ErbB1/HER1, ErbB2, HER2/neu, ErbB3/HER3, and ErbB4/
HER4.19 On ligand binding, the autophosphorylation of
specific tyrosine residues in the cytosolic domain of the
receptor takes place triggering a downstream signaling path-
way. Ligands for the EGFR include EGF, transforming
growth factor-a, heparin-binding EGF (HB-EGF), and am-
phiregulin. HB-EGF is expressed as a transmembrane precur-
sor and released from the cell surface after shedding of the
extracellular domain (ectodomain shedding) by zinc-
dependent metalloproteinases.19 This ligand is the mediator of
EGFR transactivation by G protein–coupled receptors. Aldo-
sterone is a known stimulus for matrix metalloproteinases.17
Among the effects proposed to result from aldosterone-
induced EGFR transactivation, Mazak et al20 determined in
vascular smooth muscle cells that aldosterone induces the
phosphorylation of extracellular signal–regulated kinase
(ERK) 1/2 kinase through EGFR activation. Interestingly,
myocardial hypertrophy has been linked to this intracellular
signaling pathway.21 Because it has been demonstrated that
EGF also stimulates NHE-1 in different cell types,22–24
including cardiac myocytes,25 we hypothesized that aldoste-
rone would be able to activate this transporter via transacti-
vation of the EGFR. Herein, we present evidence that confirm
this hypothesis.
Methods
All of the procedures followed during this investigation conform to
the Guide for the Care and Use of Laboratory Animals published by
the National Institutes of Health (publication No. 85-23, revised
1996), and the experimental protocol was approved by the animal
welfare committee of La Plata School of Medicine. Rats (body
weight: 300–400 g) were anesthetized by intraperitoneal injection of
sodium pentobarbital (35 mg/kg of body weight) and hearts rapidly
excised when plane 3 of phase III of anesthesia was reached.
Cell Isolation
Rat ventricular myocytes were isolated according to the technique
described previously26 from 4-month–old Wistar rats.
Intracellular pH Measurements
Intracellular pH (pHi) was measured in single myocytes with an
epi-fluorescence system (Ion Optix, Milton, MA) using the previ-
ously described 29-79-bis(carboxyethyl)-5(6)-carboxyfluorescein
technique.27
Determination of p90RSK and
NHE-1 Phosphorylation
p90RSK and NHE-1 phosphorylation were determined by Western
blots with phosphospecific antibodies as described previously.28
Measurements of Superoxide Anion Production
We used lucigenin-enhanced chemiluminescence to measure super-
oxide anion production by rat cardiac tissue in Krebs-Hepes buffer
with 5 mmol/L of lucigenin, as described previously.29 An expanded
Methods section is available in the online Data Supplement at
http://hypertension.ahajournals.org.
Results
Effect of Aldosterone on NHE-1 Activity: Role of
the MR
We investigated the effect of aldosterone on acute NHE-1
activity during the recovery of an acid load in rat ventricular
myocytes. Figure 1A shows the effect of exposing a rat
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Figure 1. Aldosterone induced activation of the Na1/H1
exchanger (NHE-1). A, Representative traces of intracellular pH
(pHi) during the application of 2 consecutive ammonium pulses
(20 mmol/L of NH4Cl), in the absence (first pulse) and presence
of 10 nmol/L of aldosterone (aldo; second pulse). Aldo was
applied 10 minutes before the second pulse. B, Average proton
efflux (JH), carried by the NHE-1, before (first pulses; Œ; n55)
and after application of 10 nmol/L of aldo (second pulses; F;
n55). *P,0.05 vs control. C, Average increase in JH at pHi 6.8
expressed as the difference between the second and the first
pulse, in the presence of 10 nmol/L of aldo (n55) and in the
presence of aldo plus spironolactone (spiro; 10 mmol/L; n55),
plus eplerenone (eple; 10 mmol/L; n56), plus mifepristone
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ventricular myocyte to aldosterone (10 nmol/L) 10 minutes
before the beginning of the ammonium pulse. The hormone
significantly increases the proton efflux (JH) at acidic pHi
(Figure 1B). According to a rapid effect, preincubation of the
myocytes with cycloheximide (inhibitor of protein synthesis,
10 mmol/L) did not prevent the stimulatory effect of aldoste-
rone on NHE-1–mediated pHi recovery (Figure 1C). The
effect of aldosterone was abolished by pretreatment of the
cells with the MR antagonists spironolactone (10 mmol/L) or
eplerenone (10 mmol/L), indicating that the MR participates
in such rapid effect of aldosterone (Figure 1C). In addition,
mifepristone (glucocorticoid receptor antagonist, 1 mmol/L)
did not affect the aldosterone-mediated NHE-1 stimulation,
confirming that aldosterone specifically activated the MR
(Figure 1C). Although higher basal JH was observed with
spironolactone, eplerenone, and cycloheximide (Figure
1C, inset), no statistical significance was attained with any
of the drugs used. To confirm that spironolactone (which
produced the greatest effect on basal JH) was not truly
significantly affecting basal JH, we performed experiments
in which we added spironolactone only to the second
ammonium pulse, the first one being the control in the
absence of the drug. Under these conditions, no effect of
spironolactone was detected (DJH at pHi 6.8:
0.0960.25 mmol/L per minute; n55), further indicating
that this drug does not affect basal JH.
Involvement of EGFR Transactivation in
Aldosterone-Induced NHE-1 Stimulation
To investigate whether the aldosterone-induced NHE-1 stim-
ulation is mediated by EGFR transactivation, the myocytes
were pretreated with AG1478 (EGFR kinase inhibitor,
1 mmol/L) 10 minutes before the addition of aldosterone.
Figure 2A and 2B shows that AG1478 prevented aldosterone-
induced NHE stimulation during pHi recovery from acidosis.
As mentioned above, EGF is released from the cell surface by
zinc-dependent metalloproteinases19 and mediates the EGFR
transactivation by G protein–coupled receptors. Aldosterone
is a known stimulus for matrix metalloproteinases.17 Thus, we
measured pHi in the presence of the inhibitor of the metallo-
proteinases, matrix metalloproteinase inhibitor II. This
compound inhibited the effects of aldosterone (Figure 2C),
indicating that this hormone is promoting the release of
EGF from the cell, which, in turn, activates the EGFR.
Because the src-kinase is known to be involved in EGFR
transactivation in various scenarios,14 we evaluated the
effect of aldosterone in the presence of PP1, a selective
inhibitor of src-kinase. Under these conditions, aldosterone
failed to stimulate the NHE-1 (Figure 2C), suggesting that
the src-kinase participates in the EGFR transactivation
promoted by the steroid.
Effects of Exogenous EGF on NHE-1 Activity
To confirm that EGFR activation was able to stimulate
NHE-1 activity in cardiac myocytes, we pretreated the
cells with exogenous EGF (0.1 mg/mL). Figure 3 shows
that the addition of EGF to the extracellular medium
Figure 1 (Continued). (miphe; 1 mmol/L; n54), or plus cyclo-
heximide (ciclohex; 10 mmol/L; n55). *P,0.05 vs aldo. Inset,
Average absolute values of basal JH (recovery from the first of
the 2 consecutive ammonium pulses) at pHi 6.8 recorded in the
absence (control) or presence of spironolactone, eplerenone,
mifepristone, or cycloheximide.
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Figure 2. A, Representative traces of intracellular pH (pHi) dur-
ing the application of 2 consecutive ammonium pulses
(20 mmol/L of NH4Cl), in the absence (first pulse) and presence
of 10 nmol/L of aldosterone (aldo; second pulse). AG1478 (AG;
1 mmol/L) was applied 10 minutes before the first pulse and
maintained throughout the experiment. Aldo was applied 10
minutes before the second pulse. B, Average proton efflux (JH),
carried by the Na1/H1 exchanger (NHE-1), before (first pulses;
E; n54) and after application of 10 nmol/L of aldo (second
pulses; F; n54) in the continuous presence of 1 mmol/L of AG.
C, Average JH obtained at pHi of 6.8 in the presence of the
matrix metalloproteinase inhibitor II (3 mmol/L; n55) or the src-
kinase blocker PP1 (20 mmol/L; n55) in the absence and pres-
ence of aldo (10 nmol/L).
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significantly increased JH to a similar extent to that
observed with aldosterone, an effect that was prevented by
AG1478. As shown in Figure 3C and 3D, the average
magnitude of the effect at acidic pH and the average time
to full recovery from maximal acidosis with aldosterone or
EGF were similar, further supporting the idea that EGFR
activation is mediating the stimulation of NHE-1 induced
by aldosterone.
Role of p90RSK in EGFR Transactivation
by Aldosterone
To demonstrate that aldosterone is able to activate the ERK
1/2-p90RSK cascade through the EGFR transactivation under
our conditions, we determined the phosphorylation state of
p90RSK in rat ventricular myocardium pretreated with aldo-
sterone in the absence and presence of AG1478 or matrix
metalloproteinase inhibitor II. As shown in Figure 4A,
aldosterone significantly enhanced p90RSK phosphorylation
level, an effect that was canceled by both the EGFR and the
metalloproteinases inhibitors.
Considering that p90RSK phosphorylates the cytosolic tail
of the exchanger, we decided to explore NHE-1 phosphory-
lation by a phosphospecific antibody, which recognizes the
phospho-Ser703 in the 14-3-3 protein binding motif of the
NHE-1 carboxyl tail. Aldosterone significantly increased
NHE-1 phosphorylation at Ser703, and pretreatment with
AG1478 or matrix metalloproteinase inhibitor II prevented
this effect (Figure 4B).
We next analyzed the phosphorylation state of NHE-1
Ser703 after the myocardium pretreatment with exogenous
EGF. As expected, EGF increased NHE-1 phosphorylation,
an effect that was prevented by AG1478 (Figure S1, available
in the online Data Supplement).
Role of Reactive Oxygen Species in EGFR
Transactivation by Aldosterone
It has been demonstrated that both aldosterone30–33 and
EGF34 stimulate reactive oxygen species (ROS) production.
To test that aldosterone or EGF is also inducing the formation
of ROS in rat myocardium, we measured superoxide anion by
the lucigenin method. Figure S2 depicts the increase in
superoxide anion generation after aldosterone (Figure S2A)
or EGF (Figure S2B) treatment and the inhibition of these
effects by AG1478, indicating that aldosterone increases the
production of ROS via transactivation of EGFR, consistent
with the effects of this hormone on NHE-1 phosphorylation
and stimulation. As expected, Figure S2 also shows that
spironolactone or PP1 canceled the effect of aldosterone but
not that of EGF, suggesting that EGFR transactivation occurs
downstream from the activation of the MR and the src-kinase
and that the MR is not stimulated after EGF binding to its
receptor. Spironolactone, AG1478, and PP1 did not affect the
basal production of superoxide anion.
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Figure 3. Epidermal growth factor (EGF) induced activation of the Na1/H1 exchanger (NHE-1). A, Representative traces of intracelluar
pH (pHi) during the application of 2 consecutive ammonium pulses (20 mmol/L of NH4Cl), in the absence (first pulse) and presence of
0.1 mg/mL of EGF (second pulse). EGF was applied 10 minutes before the second pulse. B, Average proton efflux (JH) carried by the
NHE-1 before (first pulses; M; n55) and after application of 0.1 mg/mL of EGF (second pulses; f; n55). *P,0.05 vs control. C, Average
increase in JH at pHi 6.8 expressed as the difference between the second and the first pulse, in the presence of aldo (n55) or EGF
(n55). D, Average time to reach steady-state pH values from maximal acidosis in the absence and presence of aldo (n55) or EGF
(n55). *P,0.05 vs control.
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Finally, we aimed to determine whether the ROS generated
by aldosterone or EGF results in NHE-1 stimulation. As
depicted in Figure S3, the effects of both hormones were
abolished by pretreatment of the myocytes with the ROS
scavenger N-2-mercaptopropionyl glycine (2 mmol/L), sug-
gesting that ROS act as signaling molecules in the pathway
triggered by transactivation of EGFR.
Discussion
Although for a long time aldosterone was exclusively seen as
the most important antinatriuretic hormone exerting this
effect through the intracellular MR acting as a transcription
factor, early reports also called attention to the rapid non-
genomic effects of this hormone.35,36 In the present work we
present for the first time that aldosterone stimulates cardiac
NHE-1 through a rapid nongenomic and MR-dependent
effect via the transactivation of EGFR, which, in turn,
produces ROS and activates the ERK 1/2-p90RSK cascade.
Nongenomic but MR-independent activation of NHE-1 in-
duced by aldosterone was described previously in the rat
heart.10,11 On the other hand, and in agreement with our data,
Michea et al37 determined that this nongenomic effect of the
hormone was mediated by its binding to the MR. More
recently, it was reported in vascular smooth muscle that
certain nongenomic effects of aldosterone were attributed to
simultaneous activation of MR and a surface membrane G
protein–coupled receptor, the GPR30.38 These investigators
also reported that the MR pharmacological inhibitors used by
us behave as partial antagonists of the GPR30.38 Further
research would be necessary to elucidate the potential in-
volvement of this type of receptor in our experimental
conditions.
A similar signaling pathway to the one described by us was
also proposed by Downey’s group39–41 to explain Akt-
dependent mitochondrial ROS production after EGFR acti-
vation. More interestingly, Gekle et al,42 working with
cultured Madin-Darby canine kidney cells, described the
activation of the ERK 1/2 intracellular pathway after aldoste-
rone-induced EGFR transactivation. These authors also sug-
gested the NHE-1 as one of the end point targets of this
mechanism present in the Madin-Darby canine kidney cells,42
in agreement with the results obtained in cardiac myocytes
presented herein.
Increasing body of evidence demonstrate that ROS also act
as physiological signaling molecules of diverse intracellular
pathways.43 Moreover, cumulative data indicate that oxida-
tive stress plays a key role in the development of cardiac
hypertrophy and failure. It was demonstrated previously that
exposure of rat myocytes to exogenous hydrogen peroxide
leads to NHE-1 stimulation after activation of mitogen-acti-
vated protein kinase signaling.25,44 One of these studies also
involved the EGFR in this effect.25 In cat ventricular myo-
cytes, we have described a singular mechanism that involves
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Figure 4. Aldosterone-induced p90RSK and Na1/H1 exchanger (NHE-1) phosphorylation. A, p90RSK activation was determined by im-
munoblot with a specific antibody to the phosphorylated form of the kinase (control: n54). Aldosterone induced a significant increase in
its phosphorylation (n54), an effect that was prevented by the EGFR antagonist AG1478 (1 mmol/L; n54) and the inhibitor of the matrix
metalloproteinase inhibitor II (MMPI; 3 mmol/L; n54). Neither AG1478 (92.01611.51%; n54) nor MMPI (95.5067.98%; n54) affected
basal phosphorylation of the kinase, and no differences in total p90RSK were observed between experimental groups. Representative
Western blot bands are shown on top. Bars correspond with averaged 6 SEM results for each group. The inhibitors and aldosterone
were applied 15 and 10 minutes before freezing the ventricular slices, respectively. B, Aldosterone-induced activation of p90RSK was
accompanied by an increase in NHE-1 phosphorylation at Ser703 (n54; control: n54), estimated by a specific antibody against the P-14-
3-3 binding motif (BM). This effect was prevented by the EGFR antagonist AG1478 (n54) and the inhibitor of the MMPI (n54). Again, a repre-
sentative Western blot is shown on top, whereas averaged 6 SEM results are expressed in the bar chart. *P,0.05 vs all other groups,
ANOVA. The inhibitors and aldosterone were applied 15 and 10 minutes before freezing the ventricular slices, respectively.
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an autocrine action of endothelin 1 released from the myocyte
by angiotensin II that presents the NHE-1 as an end point
target of ROS acting as second messengers.27,45 More re-
cently, another study from our group showed that mitochon-
drial ROS are involved in NHE-1 stimulation produced by
EGFR transactivation triggered by stretching cat papillary
muscles.34 In agreement with these studies, we suggest herein
that transactivation of EGFR induced by aldosterone also
involves ROS as mediators of NHE-1 stimulation. Although
we did not aim to investigate the source of ROS in the present
study, based on our previous work we can speculate that they
are being released from mitochondria.
Pharmacological inhibition of the src-kinase or the metal-
loproteinases canceled the effect of aldosterone on NHE-1
stimulation. The src-kinase has been postulated previously as
a link between MR activation and EGFR transactivation17 and
between G-coupled receptor activation and metalloproteinase
stimulation.34,46 We have also demonstrated that blockade of
the src-kinase inhibited ROS production induced by aldoste-
rone but not by EGF. Accordingly, Grossmann et al,47
working with Chinese hamster ovary cells transfected with
the MR, reported that ERK 1/2 phosphorylation induced by
aldosterone but not that induced by EGF was inhibited by
src-kinase blockade. Taken together, these data suggest that
the src-kinase is the most likely candidate to be the link
between the MR and metalloproteinase activation.
The results of the present work suggest for the first time
that some deleterious cardiovascular effects of aldosterone
could in fact be mediated by EGFR transactivation. Several
studies have shown a close relationship between EGFR
activation and cardiac hypertrophy. Neonatal and adult car-
diomyocytes respond to both neurohumoral and mechanical
growth stimuli with a marked increase in HB-EGF mRNA,
which act as an early response gene to facilitate hypertrophic
growth in these cells.48 Consistently, overexpressed HB-EGF
significantly induced hypertrophy of cardiomyocytes and
proliferation of cardiac fibroblasts.49 Moreover, upregulated
HB-EGF exacerbated remodeling at the subacute and chronic
stages postmyocardial infarction, elevating the levels of
apoptosis, fibrosis, and the accumulation of myofibroblasts
and macrophages, in addition to inducing left ventricular
hypertrophy.49 Zhai et al50 demonstrated that mutations in a
conserved YIPP motif in the C terminus of angiotensin II type
1 receptors, which is essential for EGFR transactivation,
diminished this process and inhibited cardiac hypertrophy.
More recently, it has been shown that the flavonoid silibinin
has the potential to protect against cardiac hypertrophy,
inflammation, and fibrosis by blocking EGFR activity and
EGFR-dependent different intracellular signaling pathways.21
Future investigation is necessary to elucidate whether these
pathological effects of EGFR activation are in fact triggered
by MR stimulation.
Perspectives
In the last years, the employment of new methods for
screening hyperaldosteronism has revealed an important
prevalence of this disease among the hypertensive patients.51
This disease carries significant deleterious effects in heart and
blood vessels, including myocardial fibrosis and endothelial
dysfunction.51,52 These patients also present higher left ven-
tricular hypertrophy than essential hypertensive subjects.53 In
connection with this, clinical trials like the Randomized
Aldactone Evaluation Study, Eplerenone Postacute Myocar-
dial Infarction Heart Failure Efficacy and Survival Study,
and, more recently, the Eplerenone in Mild Patients Hospi-
talization and Survival Study in Heart Failure,4 show the
unequivocal beneficial effects of aldosterone inhibition in
cardiac failure. The addition of an MR antagonist to the
regular therapy reduced mortality by 30% in patients with
cardiac failure and by 15% in patients with left ventricular
dysfunction after acute myocardial infarction, respectively.1–3
The mechanism of action by which aldosterone inhibition
improves cardiac failure is not perfectly defined.54 Because
Na1 and Ca21 overload triggered by NHE-1 upregulation
seems to be a well-accepted cause of myocardial hypertrophy
and heart failure,55–58 and recent studies suggest that activa-
tion of the NHE-1 is sufficient to generate Ca21 signals that
induce cardiac hypertrophy and heart failure,56,59 the results
obtained in the present study offer an explanation for the
successfulness of MR inhibition in these circumstances. We
could speculate, based in the evidence quoted before, that the
decrease in ROS formation and the “deactivation” of the
NHE-1 may be main contributors to the beneficial effects of
aldosterone inhibition. We can also speculate that not only
NHE-1 inhibition but also the inhibition of the upstream
signals, like metalloproteinases, HB-EGF, and EGFR, would
be beneficial interventions in myocardial hypertrophy and/or
heart failure.
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